Saxagliptin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Saxagliptin and local guidelines before prescribing.
DPP-4 inhibitor
Mechanism
DPP-4 inhibitor.
Uses
Type 2 diabetes.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Nasopharyngitis, headache, heart failure hospitalisation risk, pancreatitis.
Interactions
CYP3A4 inhibitors raise levels.
Contraindications and cautions
Pancreatitis history
Monitoring
HbA1c
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose in renal impairment
Overdose and reversal
Supportive
Special advice
Caution in heart failure.
More from the textbook: uses, cautions and other points
- Risks - pancreatitis, bullous pemphigoid ; saxagliptin and alogliptin - caution in heart failure.
Endocrine: Anatomy Physiology and Pharmacology - Saxagliptin and alogliptin carry a heart failure caution.
Endocrinology: Diabetes - Heart failure: Common in diabetes. Use SGLT2 inhibitors; avoid pioglitazone, and saxagliptin/alogliptin with caution.
Endocrinology: Diabetes - Alogliptin and saxagliptin.
Endocrinology: Diabetes
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Diabetes (3 mentions)